Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Setipiprant
Cat. No.:
0225LY-1137
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Setipiprant is a selective, orally available CRTh2 antagonist (IC50: 6.0 nM) used to study inflammatory responses in asthma and allergies by blocking PGD2-mediated chemotaxis.
Synonym:
KYTH-105; ACT-129968; 866460-33-5; Setipiprant; 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid; 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid; ACT129968; 5H-Pyrido(4,3-b)indole-5-acetic acid, 8-fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-; 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid
CAS No.:
866460-33-5
Compound CID:
49843471
Formula:
C24H19FN2O3
Formula Weight:
402.42
Specification
Targets&IC50:
CRTH2: 6.0 nM
Relative Density:
1.37 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Setipiprant can be used in respiratory research to examine the antagonism of the CRTH2 receptor in allergic inflammation.
Library Information
Target:
DP2
Receptor:
CRTh2
Pathways:
Immunology/Inflammation; Endocrinology/Hormones; GPCR/G protein signaling
Plate Number:
AOCL-15
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
45 mg/mL; 111.82 mM
